Seeking Alpha

Chelsea Therapeutics (CHTP) tumbles 23% after the FDA asks for an additional study to show the...

Chelsea Therapeutics (CHTP) tumbles 23% after the FDA asks for an additional study to show the durability of the company's Northera drug over a 2-3 month period. The request comes despite an agency panel recommending approval of Northera, which is designed to help stop patients with conditions like Parkinson's disease from tumbling.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs